ArticleCureus2025
Treatment Pathways and Outcomes in Unresectable Gastric Cancer: A Retrospective Cohort Analysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe surgical management of advanced gastric cancer (AGC) ranges from diagnostic surgery (DS) to palliative procedures (PP) and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). This study aimed to describe real-world surgical strategies and evaluate their impact on patient outcomes.
methodsWe retrospectively analyzed 158 patients with AGC treated between 2014 and 2024 at a tertiary center and categorized them into three groups: DS (n=94), PP (n=52), and CRS-HIPEC (n=12). Demographic data, perioperative outcomes, and survival metrics were compared using ANOVA, Chi-square tests, and Kaplan-Meier estimates. In the CRS-HIPEC pathway, all 12 (100%) patients underwent staging laparoscopy, multidisciplinary team review, neoadjuvant chemotherapy, and interval CRS-HIPEC.
resultsTreatment selection was influenced by disease burden, symptom profile, and physiologic reserve. Patients undergoing CRS-HIPEC were younger (mean age 49.4 years, p=0.002) and had higher postoperative complication rates, nine of 12 (75.0%)-compared with PP, 21 of 52 (40.4%), and DS, seven of 94 (7.4%) (p<0.001). Median overall survival was longest after CRS-HIPEC (40.3 months), followed by PP (11.5 months) and DS (7.1 months). In the CRS-HIPEC cohort, median disease-free survival was 16.6 months.
conclusionsSurgical strategies for unresectable AGC are heterogeneous and should be individualized. Palliative procedures can offer symptom relief and modest survival benefit in selected patients, though at the cost of morbidity and potential delays in systemic therapy. CRS-HIPEC, associated with prolonged survival in a small, highly selected cohort, should be regarded as hypothesis-generating. Multidisciplinary evaluation and careful patient selection remain central to optimizing outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.